Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where KYMR advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where KYMR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 02, 2025. You may want to consider a long position or call options on KYMR as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for KYMR just turned positive on June 02, 2025. Looking at past instances where KYMR's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
KYMR moved above its 50-day moving average on May 29, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KYMR crossed bullishly above the 50-day moving average on May 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 184 cases where KYMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYMR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
KYMR broke above its upper Bollinger Band on June 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.610) is normal, around the industry mean (17.331). P/E Ratio (0.000) is within average values for comparable stocks, (59.245). KYMR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (57.143) is also within normal values, averaging (261.682).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KYMR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a biotechnology company, which engages in curing untreatable diseases and focuses on discovering and developing novel small molecule therapeutics
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
DSEFX | 37.39 | 0.16 | +0.43% |
Domini Impact Equity Investor | |||
HRINX | 52.60 | N/A | N/A |
Harbor International Administrative | |||
VEMRX | 99.37 | N/A | N/A |
Vanguard Emerging Mkts Stock Idx InsPlus | |||
TQGIX | 19.09 | N/A | N/A |
T. Rowe Price Integrated Global Eq I | |||
EMPTX | 8.33 | N/A | N/A |
UBS Emerging Markets Equity Opp P2 |
A.I.dvisor indicates that over the last year, KYMR has been loosely correlated with CCCC. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if KYMR jumps, then CCCC could also see price increases.
Ticker / NAME | Correlation To KYMR | 1D Price Change % | ||
---|---|---|---|---|
KYMR | 100% | +1.04% | ||
CCCC - KYMR | 63% Loosely correlated | +11.28% | ||
NRIX - KYMR | 61% Loosely correlated | -0.49% | ||
VERA - KYMR | 58% Loosely correlated | -2.61% | ||
IMNM - KYMR | 56% Loosely correlated | +2.21% | ||
ERAS - KYMR | 54% Loosely correlated | +1.40% | ||
More |